Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Histogenics (NASDAQ:HSGX) and Helius Medical Technologies (NASDAQ:HSDT).
Histogenics (HSGX)
In a report issued on August 9, Ryan Zimmerman from BTIG maintained a Buy rating on Histogenics, with a price target of $5. The company’s shares closed on Friday at $2.44.
Zimmerman noted:
“Any day between now and early Fall investors should get Ph. 3 top-line data from HSGX. We have received investor interest asking how the stock will respond, what the appropriate way to read to the trial results will be, and how HSGX will proceed following top-line data read out. We continue to believe data will be positive based on a myriad of factors including similar clinical trials completed by competitive products, NeoCart’s Ph. 2 data and results, and anecdotal feedback from patients in the Ph. 3 NeoCart trial. The 15% dual-responder rate analysis is an achievable bar in our view, as NeoCart’s Ph. 2 responder rate was well above this threshold. Even if the point score improvements are not perfect, if the responder analysis is strong, we expect BLA submission and subsequent approval to follow.”
According to TipRanks.com, Zimmerman is a 5-star analyst with an average return of 29.9% and a 69.0% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, OrthoPediatrics Corp, and SeaSpine Holdings.
Histogenics has an analyst consensus of Strong Buy, with a price target consensus of $4.17.
See today’s analyst top recommended stocks >>
Helius Medical Technologies (HSDT)
BTIG analyst Sean Lavin maintained a Hold rating on Helius Medical Technologies on August 10. The company’s shares closed on Friday at $9.11.
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 13.7% and a 61.2% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Boston Scientific Corp.
The word on The Street in general, suggests a Hold analyst consensus rating for Helius Medical Technologies with a $14 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
